Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
156 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06731907 | A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01) | recruiting | Phase 2 | 90 | Merck Sharp & Dohme LLCINDUSTRY | 11 | Aug 18, 2026 | clinicaltrials |
| NCT05254743 | A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)(BRUIN-CLL-314) | recruiting | Phase 3 | 737 | Loxo Oncology, Inc.INDUSTRY |
| 23 |
| Aug 17, 2026 |
| clinicaltrials |
| NCT02300766 | Cerebellar Mutism Syndrome Study | recruiting | — | 2,000 | Rigshospitalet, DenmarkOTHER | 14 | Aug 12, 2026 | clinicaltrials |
| NCT06801834 | Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer(EVOKE-SCLC-04) | recruiting | Phase 3 | 695 | Gilead SciencesINDUSTRY | 23 | Aug 12, 2026 | clinicaltrials |
| NCT07752238 | Diagnostic Prediction Model for De Novo Metastatic Breast Cancer | recruiting | — | 925 | Markusovszky University Teaching Hospital os County VasOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06203210 | A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer(IDeate-Lung02) | recruiting | Phase 3 | 540 | Daiichi SankyoINDUSTRY | 23 | Aug 6, 2026 | clinicaltrials |
| NCT07743021 | Health for Hungary (H4H) - Longitudinal Collection of Blood Samples and Corresponding Data(H4H) | recruiting | — | 15,000 | Center for Molecular Fingerprinting Research Nonprofit LLCOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT01804686 | A Long-term Extension Study of PCI-32765 (Ibrutinib)(CAN3001) | recruiting | Phase 3 | 700 | Janssen Research & Development, LLCINDUSTRY | 30 | Jul 31, 2026 | clinicaltrials |
| NCT07039916 | Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis | recruiting | Phase 3 | 231 | Immunovant Sciences GmbHINDUSTRY | 15 | Jul 30, 2026 | clinicaltrials |
| NCT07044336 | Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | recruiting | Phase 3 | 800 | AstraZenecaINDUSTRY | 28 | Jul 29, 2026 | clinicaltrials |
| NCT06472245 | Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor(ARTEMIA) | recruiting | Phase 3 | 363 | OSE ImmunotherapeuticsINDUSTRY | 14 | Jul 23, 2026 | clinicaltrials |
| NCT04970056 | Pancreatic Cancer Early Detection Consortium(PRECEDE) | recruiting | — | 20,000 | Arbor Research Collaborative for HealthOTHER | 11 | Jul 22, 2026 | clinicaltrials |
| NCT05142189 | Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer(LuCa-MERIT-1) | recruiting | Phase 1 | 320 | BioNTech SEINDUSTRY | 8 | Jul 22, 2026 | clinicaltrials |
| NCT06072131 | To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL(CRESCENDO) | recruiting | Phase 3 | 504 | Acrotech Biopharma Inc.INDUSTRY | 10 | Jul 22, 2026 | clinicaltrials |
| NCT05327894 | Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia(Interfant-21) | recruiting | Phase 3 | 160 | Princess Maxima Center for Pediatric OncologyOTHER | 24 | Jul 10, 2026 | clinicaltrials |
| NCT07689331 | Hungarian National Systemic Amyloidosis Registry(AMYREG) | recruiting | — | 300 | Semmelweis UniversityOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06819007 | Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)(DO-01) | recruiting | Phase 3 | 582 | Daiichi SankyoINDUSTRY | 25 | Jul 2, 2026 | clinicaltrials |
| NCT06216301 | LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC(LUNAR-2) | recruiting | Phase 3 | 734 | NovoCure GmbHINDUSTRY | 16 | Jun 25, 2026 | clinicaltrials |
| NCT00196742 | Fabry Disease Registry & Pregnancy Sub-registry | recruiting | — | 9,000 | Genzyme, a Sanofi CompanyINDUSTRY | 44 | Jun 23, 2026 | clinicaltrials |
| NCT05742607 | IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) | recruiting | Phase 2 | 70 | Innate PharmaINDUSTRY | 5 | Jun 17, 2026 | clinicaltrials |
| NCT05208047 | (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors | recruiting | Phase 3 | 482 | Cogent Biosciences, Inc.INDUSTRY | 22 | Jun 16, 2026 | clinicaltrials |
| NCT04844866 | Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients(DALY 2-EU) | recruiting | Phase 2 | 213 | Miltenyi Biomedicine GmbHINDUSTRY | 14 | Jun 10, 2026 | clinicaltrials |
| NCT03093116 | A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements(TRIDENT-1) | recruiting | Phase 1 / Phase 2 | 500 | Turning Point Therapeutics, Inc.INDUSTRY | 19 | May 27, 2026 | clinicaltrials |
| NCT06256588 | A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma(JADE) | recruiting | Phase 3 | 864 | GlaxoSmithKlineINDUSTRY | 31 | May 26, 2026 | clinicaltrials |
| NCT06588478 | A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | recruiting | Phase 2 | 249 | Loxo Oncology, Inc.INDUSTRY | 18 | May 19, 2026 | clinicaltrials |
| NCT06757634 | Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) | recruiting | Phase 3 | 1,180 | Celcuity IncINDUSTRY | 22 | May 18, 2026 | clinicaltrials |
| NCT06697301 | Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma. | recruiting | Phase 2 / Phase 3 | 740 | Eikon TherapeuticsINDUSTRY | 24 | May 8, 2026 | clinicaltrials |
| NCT04043494 | International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma(LBL 2018) | recruiting | Phase 3 | 683 | University Hospital MuensterOTHER | 21 | May 6, 2026 | clinicaltrials |
| NCT04256317 | A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) | recruiting | Phase 2 / Phase 3 | 316 | Taiho Oncology, Inc.INDUSTRY | 10 | Apr 30, 2026 | clinicaltrials |
| NCT06688851 | Patient Specific Implants (PSIs) for the Decompression of Odontogenic Cysts | recruiting | — | 20 | Semmelweis UniversityOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06713993 | Semmelweis Esophageal Cancer Study: Noninvasive Prognostic Parameters in Patients With Oesophageal and Esophagogastric Junction Cancer | recruiting | — | 100 | Semmelweis UniversityOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06064877 | A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma(FIERCE-HN) | recruiting | Phase 3 | 410 | AVEO Pharmaceuticals, Inc.INDUSTRY | 18 | Apr 9, 2026 | clinicaltrials |
| NCT05203172 | The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials | recruiting | Phase 4 | 46 | PfizerINDUSTRY | 17 | Apr 7, 2026 | clinicaltrials |
| NCT05304377 | A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia(CML) | recruiting | Phase 1 | 250 | Enliven TherapeuticsINDUSTRY | 14 | Apr 1, 2026 | clinicaltrials |
| NCT06093672 | Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera(GIV-IN-PV) | recruiting | Phase 3 | 220 | ItalfarmacoINDUSTRY | 16 | Mar 25, 2026 | clinicaltrials |
| NCT02790983 | Primary Tumor Research and Outcomes Network(PTRON) | recruiting | — | 1,350 | AO Innovation Translation CenterOTHER | 9 | Feb 25, 2026 | clinicaltrials |
| NCT06112314 | IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)(PRISM-MEL-301) | recruiting | Phase 3 | 680 | Immunocore LtdINDUSTRY | 26 | Feb 25, 2026 | clinicaltrials |
| NCT05270096 | International Leukemia Target Board(iLTB) | recruiting | — | 600 | Princess Maxima Center for Pediatric OncologyOTHER | 7 | Jan 9, 2026 | clinicaltrials |
| NCT02986516 | Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized Disease(SACRO) | recruiting | N/A | 100 | Italian Sarcoma GroupNETWORK | 10 | Jan 2, 2026 | clinicaltrials |
| NCT06465433 | Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab | recruiting | Phase 2 | 25 | Incyte CorporationINDUSTRY | 5 | Dec 10, 2025 | clinicaltrials |
| NCT07086989 | Cardiovascular Risk in Children With Chronic Conditions Study(CR3C) | recruiting | — | 300 | Semmelweis UniversityOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors(SPARTA) | recruiting | Phase 2 | 497 | Apollomics Inc.INDUSTRY | 11 | Jun 27, 2025 | clinicaltrials |
| NCT05711992 | Rare Embryonal Tumors of the Central Nervous System: International Registry | recruiting | — | 300 | Immune Oncology Research InstituteOTHER | 9 | May 8, 2025 | clinicaltrials |
| NCT06730815 | Body Image and Physical Activity of Women with Breast Cancer | recruiting | — | 300 | University of PecsOTHER | 1 | Dec 19, 2024 | clinicaltrials |
| NCT06719232 | Evaluating the Efficacy and Patient Experience of Catheter-Free Intravesical Instillation(NOCATIN) | recruiting | — | 300 | Jahn Ferenc South Pest Teaching HospitalOTHER_GOV | 1 | Dec 12, 2024 | clinicaltrials |
| NCT05797831 | Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer | recruiting | Phase 2 / Phase 3 | 268 | Kartos Therapeutics, Inc.INDUSTRY | 17 | May 2, 2024 | clinicaltrials |
| NCT06167135 | Polycystic Ovary Syndrome, Mitochondrial Dysfunction, Obesity, Insulin Resistance Infertility (POMODORI) Cohort(POMODORI) | recruiting | — | 150 | Semmelweis UniversityOTHER | 1 | Dec 18, 2023 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials